DEXTROGEL FAST ACTING DEXTROSE GEL 3 X 25G - 1 BOX

Product Information

to consult a physician in case of signs and symptoms (breast development or other sexual changes) in a child that may have been exposed accidentally to Oestrogel. The overall evidence shows an increased risk of breast cancer in women taking combined oestrogen-progestogen or oestrogen-only HRT, that is dependent on the duration of taking HRT.

Infants who became hypoglycaemic (< 2.6 mmol/L) were encouraged to feed (determined by maternal choice) and were randomised to receive 40% oral dextrose gel (0.5 mL/kg) (n = 118) or placebo gel (n = 119) massaged into the buccal membrane. For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used. High certainty: we are very confident that the true effect lies close to that of the estimate of effect. Treatment with surface active agents ( e.g. sodium lauryl sulphate), or other drugs which alter barrier structure or function, could remove drug bound to the skin, altering transdermal flux. Therefore, patients should avoid the use of strong skin cleansers and detergents ( e.g. benzalkonium or benzothonium chloride products), skin care products of high alcoholic content (astringents, sunscreens) and keratolytics ( e.g. salicylic acid, lactic acid).fill the dropper up to the graduated mark for a daily dose of vitamin K that is comparable to infant formula feed products dropwise, each day children who are wholly or largely fed with breast milk should receive vitamin K on the second day following birth until ad including the third month of their lives. Use a disposable needle, syringe, or prefilled syringe only once. Follow any state or local laws about throwing away used needles and syringes. Use a puncture-proof "sharps" disposal container (ask your pharmacist where to get one and how to throw it away). Keep this container out of the reach of children and pets. Since the first version of this review ( Weston 2016), data have been made available for the co‐primary outcome of correction of hypoglycaemic events and for some secondary outcomes on the effects of oral dextrose gel on individual episodes of hypoglycaemia. One of the included studies has reported follow‐up data on neurodevelopmental and disability outcomes at 4.5 years ( Harris 2013), including behavioural problems and hearing impairment, which were previously unavailable.

The metabolism of oestrogens may be increased by concomitant use of substances known to induce drug-metabolising enzymes, specifically cytochrome P450 enzymes, such as anticonvulsants ( e.g. phenobarbital, phenytoin, carbamazepine) and anti- infectives ( e.g. rifampicin, rifabutin, nevirapine, efavirenz). The increased risk in users of oestrogen-only therapy is lower than that seen in users of oestrogen-progestogen combinations. Formula milk is often given to hypoglycaemic infants. Since the carbohydrate content of breast milk on the first day is low ( Saint 1984), formula milk may be more effective than breast milk as a treatment for infants with neonatal hypoglycaemia. One post hoc analysis of a randomised trial showed that in 277 late preterm and term infants with hypoglycaemia, formula feeding was associated with the greatest increase in glucose concentration within 48 hours after birth compared with no milk, breastfeeding or expressed milk ( Weston 2017). Dextrose and placebo gels were identical in appearance. Clinicians, families and study investigators were masked to treatment allocation until completion of data analysis.Investigators in a randomised trial assessed intravenous dextrose and glucagon (200 ug/kg) or intragastric medium chain triglycerides (5 mL/kg) ( Hawdon 1993). Both treatments substantially increased the blood glucose concentration among infants already receiving 5 mcg/kg/min intravenous dextrose for hypoglycaemia. Daily application of 2.5 g or 5 g Oestrogel over a surface area of 400-750 cm 2 results in a gradual increase in oestrogen blood levels to steady state after approximately 3-5 days and provides circulating levels of both oestradiol and estrone equivalent in absolute concentrations and in their respective ratio to those obtained during the early-mid follicular phase of the menstrual cycle. Maximum serum concentrations (C max) of oestradiol and estrone on Day 12 were 117 pg/ml and 128 pg/ml, respectively. Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; Results suggest that oral dextrose gel probably corrects individual episodes of low blood glucose levels and may result in a slight reduction in the risk of major disability at age two years or older; however, the evidence is uncertain. The evidence was not sufficient to show whether oral dextrose gel reduces the need for other treatments. Oral dextrose gel compared to placebo gel probably reduces mother‐infant separation and probably increases the likelihood of exclusive breastfeeding after discharge from the hospital. Researchers reported no adverse eventswhen oral dextrose gel was given to infants.

Disclosure: 3 of the authors of this review (PJW, DLH and JE Harding) were involved in the design and conduct of this study. The effect of oestrogens on the bone mineral density is dose-dependent. Protection appears to be effective for as long as treatment is continued. After discontinuation of HRT, bone mass is lost at a similar rate to that in untreated women. HRT, especially oestrogen-progestogen combined treatment, increases the density of mammographic images which may adversely affect the radiological detection of breast cancer. If you are allergic to dextrose gel and liquid; any part of dextrose gel and liquid; or any other drugs, foods, or substances. Tell your doctor about the allergy and

Oestrogens may cause fluid retention, and therefore patients with cardiac or renal dysfunction should be carefully observed. HRT is associated with a 1.3 – 3 fold risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism. The occurrence of such an event is more likely in the first year of HRT than later (see Section 4.8). The onset of menopause results from a decline in the secretion of oestradiol and other oestrogens by the ovary resulting initially in the cessation of menstruation, followed by menopausal symptoms such as vasomotor symptoms (hot flushes and sweating), muscle cramps, myalgias, arthralgias, anxiety, atrophic vaginitis and kraurosis vulvae. Oestrogens are also an important factor in preventing bone loss and after the menopause women lose bone mineral content at an average rate of 15-20% in a ten year period.

A meta-analysis from 52 epidemiological studies reported an increased risk of ovarian cancer in women currently using HRT compared to women who have never used HRT (RR 1.43, 95% CI 1.31-1.56). For women aged 50 to 54 years taking 5 years of HRT, this results in about 1 extra case per 2000 users. In women aged 50 to 54 who are not taking HRT, about 2 women in 2000 will be diagnosed with ovarian cancer over a 5-year period. Tell all of your health care providers that you take dextrose gel and liquid. This includes your doctors, nurses, pharmacists, and dentists. Oral dextrose gel is probably an effective and safe first‐line treatment for infants with neonatal hypoglycaemia in high‐income settings. These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medicalIf a thrombophilic defect is identified which segregates with thrombosis in family members or if the defect is 'severe' ( e.g. antithrombin, protein S, or protein C deficiencies or a combination of defects) HRT is contraindicated. HRT use does not improve cognitive function. There is some evidence from the WHI trial of increased risk of probable dementia in women who start using continuous combined or oestrogen-only HRT after the age of 65. You may report side effects to the FDA at 1-800-332-1088. You may also report side effects at https://www.fda.gov/medwatch.